Home » Stocks » RIGL

Rigel Pharmaceuticals, Inc. (RIGL)

Stock Price: $4.02 USD -0.16 (-3.83%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $4.01 -0.01 (-0.25%) Jun 11, 7:58 PM
Market Cap 684.06M
Revenue (ttm) 133.88M
Net Income (ttm) -11.49M
Shares Out 169.80M
EPS (ttm) -0.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $4.02
Previous Close $4.18
Change ($) -0.16
Change (%) -3.83%
Day's Open 4.10
Day's Range 3.94 - 4.14
Day's Volume 2,604,134
52-Week Range 1.74 - 5.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOUTH SAN FRANCISCO, Calif., May 26, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is schedule...

2 weeks ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., May 14, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Alison L.

4 weeks ago - PRNewsWire

Rigel (RIGL) delivered earnings and revenue surprises of 2100.00% and 102.24%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., May 5, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2021, including sales of TAVALI...

1 month ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., April 28, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2021 financial results after market close on W...

1 month ago - PRNewsWire

The company announced positive results from an important COVID-19 clinical study.

1 month ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., April 13, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced positive topline results from a multi-center, Phase 2 clinical trial to evaluate t...

1 month ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., April 7, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the successful closing of its license agreement with Eli Lilly and Company (Lilly), ...

2 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., March 11, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the completion of patient enrollment in a multi-center Phase 2 clinical trial to ev...

3 months ago - PRNewsWire

Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.

Other stocks mentioned: AIM, ASXC, CLSN, IBIO, JAGX, OVID, VBIV
3 months ago - InvestorPlace

Rigel (RIGL) delivered earnings and revenue surprises of -10.00% and 0.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., March 2, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2020, inclu...

3 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2020 financial results after mark...

3 months ago - PRNewsWire

Here's why this stock's big run-up in recent months could be just the beginning.

3 months ago - The Motley Fool

A newly announced deal between Rigel Pharmaceuticals and sector behemoth Eli Lilly has RIGL stock climbing in trading today. The post RIGL Stock: Why Rigel Pharmaceuticals Is Climbing Today appeared fir...

3 months ago - InvestorPlace

Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

The company is teaming up with Eli Lilly on the development of a promising immune disease drug.

3 months ago - The Motley Fool

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a global exclusive license ag...

Other stocks mentioned: LLY
3 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it has been awarded $16.5 million by the U.S. Department of Defense's (DOD) Joint Pr...

4 months ago - PRNewsWire

Rigel's value proposition revolves solely around growing sales of its already approved Tavalisse for ITP in the US and worldwide and getting the label extended to include wAIHA. Tavalisse sales growth h...

4 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update, including preliminary total revenue, TAVALISSE® (fostamatinib diso...

5 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 7, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is schedule...

5 months ago - PRNewsWire

Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

Rigel's approved drug Tavalisse can be useful to cITP patients in a third line setting, but the market isn't huge. Current lead indication WIHA is not large either, and the same safety issues will make ...

6 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Dec. 4, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to TAVALISSE® (fostamatinib disodium hexahydrate) tablets will be p...

6 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif. and PETACH TIKVA, Israel, Nov. 23, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Medison Pharma (Medison) today announced that Health Canada has approve...

6 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on th...

6 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is schedul...

7 months ago - PRNewsWire

Rigel Pharmaceuticals' (RIGL) CEO Raul Rodriguez on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Rigel (RIGL) delivered earnings and revenue surprises of 33.33% and 4.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Oct. 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced enrollment of the first patients in a multicenter, Phase 2 trial to evaluate the safe...

8 months ago - PRNewsWire

Rigel Pharmaceuticals (RIGL) is developing its thrombocytopenia drug, Tavalisse, as a potential treatment for hospitalized COVID-19 patients.

8 months ago - Zacks Investment Research

Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) has announced that it will push forward with a midstage trial in the treatment of COVID-19.

8 months ago - 24/7 Wall Street

Shares of Rigel Pharmaceuticals Inc. RIGL, +1.21% were up 10.4% in premarket trading on Thursday after the company said it had started a randomized, double-blind, placebo-controlled Phase 2 clinical tri...

8 months ago - Market Watch

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.

8 months ago - PRNewsWire

Rigel has an already established asset and is expecting results from another Phase 3 trial.

8 months ago - Seeking Alpha

Rigel Is Once Again At A Bargain Price After A Temporary COVID-19 Rally

9 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, is scheduled to present a compan...

9 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 2, 2020 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to ...

9 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 21, 2020 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc.

9 months ago - PRNewsWire

Rigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Rigel (RIGL) delivered earnings and revenue surprises of 23.08% and 12.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., July 28, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.

10 months ago - PRNewsWire

Rigel Pharmaceuticals (NASDAQ: RIGL) shares are trading higher on Monday after the company announced the publication of post-hoc data analysis of TAVALISSE in the British Journal of Haematology.

10 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif., July 27, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.

10 months ago - PRNewsWire

Rigel: Fostamatinib Joins The COVID-19 Campaign And Resuscitates My Bullish Outlook

10 months ago - Seeking Alpha

The biotechnology company is hoping to improve coronavirus care.

10 months ago - The Motley Fool

Shares of Rigel Pharmaceuticals Inc. RIGL, +21.34% gained 25% in premarket trading on Tuesday after announcing that a drug used to treat an autoimmune disorder will be tested in a clinical trial in the ...

10 months ago - Market Watch

SOUTH SAN FRANCISCO, Calif., July 14, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of an investigator-sponsored trial (IST) being conducted by Imperial ...

10 months ago - PRNewsWire

About RIGL

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatme... [Read more...]

Industry
Biotechnology
IPO Date
Nov 29, 2000
CEO
Raul Rodriguez
Employees
169
Stock Exchange
NASDAQ
Ticker Symbol
RIGL
Full Company Profile

Financial Performance

In 2020, RIGL's revenue was $108.62 million, an increase of 83.21% compared to the previous year's $59.29 million. Losses were -$29.74 million, -55.54% less than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for RIGL stock is "Buy." The 12-month stock price forecast is 8.50, which is an increase of 111.44% from the latest price.

Price Target
$8.50
(111.44% upside)
Analyst Consensus: Buy